1. Home
  2. VLN vs CGTX Comparison

VLN vs CGTX Comparison

Compare VLN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valens Semiconductor Ltd.

VLN

Valens Semiconductor Ltd.

HOLD

Current Price

$2.00

Market Cap

116.9M

Sector

Technology

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

147.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLN
CGTX
Founded
2006
2007
Country
Israel
United States
Employees
233
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.9M
147.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
VLN
CGTX
Price
$2.00
$1.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$3.00
$3.33
AVG Volume (30 Days)
3.4M
1.8M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.37
N/A
Revenue Next Year
$16.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.29
52 Week High
$3.71
$3.83

Technical Indicators

Market Signals
Indicator
VLN
CGTX
Relative Strength Index (RSI) 39.03 40.65
Support Level $1.50 $0.55
Resistance Level $2.64 $1.23
Average True Range (ATR) 0.30 0.17
MACD -0.07 -0.02
Stochastic Oscillator 20.99 12.65

Price Performance

Historical Comparison
VLN
CGTX

About VLN Valens Semiconductor Ltd.

Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: